Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL. Rocconi RP, et al. Among authors: bottsford miller jn. Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7. Lancet Oncol. 2020. PMID: 33271095 Clinical Trial.
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Rocconi RP, Stevens EE, Bottsford-Miller JN, Ghamande SA, Elder J, DeMars LL, Munkarah A, Aaron P, Stanbery L, Wallraven G, Bognar E, Manley M, Horvath S, Manning L, Walter A, Galanis E, Herzog T, Monk BJ, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: bottsford miller jn. Cancer Gene Ther. 2022 Mar;29(3-4):369-382. doi: 10.1038/s41417-021-00317-5. Epub 2021 Mar 22. Cancer Gene Ther. 2022. PMID: 33753870 Clinical Trial.
Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer.
Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Ivan C, et al. Gynecol Oncol. 2013 Mar;128(3):506-11. doi: 10.1016/j.ygyno.2012.11.029. Epub 2012 Nov 28. Gynecol Oncol. 2013. PMID: 23200915 Free PMC article.
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Nick AM, et al. J Natl Cancer Inst. 2011 Nov 2;103(21):1596-612. doi: 10.1093/jnci/djr372. Epub 2011 Sep 28. J Natl Cancer Inst. 2011. PMID: 21957230 Free PMC article.
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. Stone RL, et al. Cancer Biol Ther. 2014 Jul;15(7):919-29. doi: 10.4161/cbt.28882. Epub 2014 Apr 23. Cancer Biol Ther. 2014. PMID: 24755674 Free PMC article.
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK. Merritt WM, et al. Cancer Biol Ther. 2010 Dec 15;10(12):1306-14. doi: 10.4161/cbt.10.12.13582. Epub 2010 Dec 15. Cancer Biol Ther. 2010. PMID: 20948320 Free PMC article.
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
Fader AN, Nagel C, Axtell AE, Zanotti KM, Kelley JL, Moore KN, Secord AA, Walsh CS, Huh WK, Gehrig PA, Gibbons H, Rose PG, Havrilesky LJ, Tuller E, Drake RD, Bottsford-Miller J, O'Malley DM; UPSC Consortium. Fader AN, et al. Gynecol Oncol. 2009 Mar;112(3):558-62. doi: 10.1016/j.ygyno.2008.11.016. Epub 2009 Jan 1. Gynecol Oncol. 2009. PMID: 19118888
Notch3 pathway alterations in ovarian cancer.
Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Hu W, et al. Cancer Res. 2014 Jun 15;74(12):3282-93. doi: 10.1158/0008-5472.CAN-13-2066. Epub 2014 Apr 17. Cancer Res. 2014. PMID: 24743243 Free PMC article.
Targeting SRC and tubulin in mucinous ovarian carcinoma.
Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. Liu T, et al. Clin Cancer Res. 2013 Dec 1;19(23):6532-43. doi: 10.1158/1078-0432.CCR-13-1305. Epub 2013 Oct 7. Clin Cancer Res. 2013. PMID: 24100628 Free PMC article.
37 results